| Gini, Guido |
| Recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
| Recruiting | 2 | 160 | Europe | Nivolumab 10 MG/ML | Medical University of Gdansk, Medical Research Agency | Hodgkin Lymphoma | 09/22 | 07/26 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Active, not recruiting | 2 | 75 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | DLBCL | 07/24 | 07/27 | | |
| Terminated | 2 | 37 | Europe | Copanlisib, ALIQOPA | Fondazione Italiana Linfomi - ETS | Diffuse Large B-cell Lymphoma | 12/24 | 12/24 | | |
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide |
|
|
| Terminated | 2 | 5 | Europe | Rituximab, Chemotherapy, Tenofovir alafenamide | Gruppo Italiano Malattie EMatologiche dell'Adulto | Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | 05/24 | 05/24 | | |
| Recruiting | 2 | 28 | Europe | Daratumumab, Daratumumab sc, Bortezomib, Bortezomib sc, Dexamethasone, Dexamethasone os | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | Plasmablastic Lymphoma | 01/25 | 01/25 | | |
| Active, not recruiting | 2 | 175 | Europe | Ibrutinib, Rituximab | International Extranodal Lymphoma Study Group (IELSG), Janssen-Cilag AG, F. Hoffmann La Roche Ltd, Janssen Pharmaceutica NV | Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma | 06/27 | 06/27 | | |
| Not yet recruiting | 2 | 56 | Europe | Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 09/28 | 09/33 | | |
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Withdrawn | 2 | 150 | Europe | R-DHAP, Pola-R-DHAP | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 01/29 | 01/29 | | |
NCT02916316: Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell |
|
|
| Active, not recruiting | N/A | 127 | Europe | R-CHOP with doxorubicin, R-CHOP with doxorubicin analogue, R-COMP | Fondazione Italiana Linfomi - ETS | Lymphoma, Large B-Cell, Diffuse Large B-Cell | 12/20 | 12/24 | | |
NCT04882475: Biological Insights of First Relapsed-refractory Patients With Mantle Cell Lymphoma: the MANTLE-FIRST BIO Study. |
|
|
| Recruiting | N/A | 80 | Europe | | Fondazione Italiana Linfomi - ETS | Mantle Cell Lymphoma | 03/25 | 03/25 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
NCT06156774: SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project |
|
|
| Recruiting | N/A | 130 | Europe | Chimeric Antigen Receptor T-cells (CAR-T) therapy | Fondazione Italiana Linfomi - ETS, Kite, A Gilead Company | Non-hodgkin Lymphoma,B Cell | 07/26 | 07/26 | | |
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. |
|
|
| Not yet recruiting | N/A | 125 | Europe | Zanubrutinib | Fondazione Italiana Linfomi - ETS | Waldenström's Macroglobulinemia (WM) | 07/26 | 07/26 | | |
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma |
|
|
| Not yet recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | 12/27 | 12/27 | | |
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 150 | Europe | | Fondazione Italiana Linfomi - ETS | Low Grade Non-Hodgkin's Lymphoma, Adult | 02/25 | 02/25 | | |
NCT03552003: Study for Elderly (≥ 65 Years) Patients With Classical Hodgkin Lymphoma Undergoing CGA at Diagnosis |
|
|
| Recruiting | N/A | 400 | Europe | Treatment for clinical practise | Fondazione Italiana Linfomi ONLUS | Classical Hodgkin Lymphoma | 01/26 | 01/26 | | |
NCT05934084: Lifestyles Implemented-Survivorship Care Plan in Lymphoma Survivors |
|
|
| Recruiting | N/A | 552 | Europe | Lifestyles Implemented-Survivorship Care Plan (LS-SCP) | Fondazione Italiana Linfomi - ETS | Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL) | 02/26 | 02/26 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
| Patti, Caterina |
TRIANGLE, NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma |
|
|
| Recruiting | 3 | 870 | Europe | R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance) | Prof. Dr. M. Dreyling (co-chairman), LMU Klinikum | Mantle Cell Lymphoma | 05/21 | 05/26 | | |
|
| Active, not recruiting | 3 | 128 | Europe | R2-MANT, Rituximab and Lenalidomide (R2), R-MANT, Rituximab (R) | Fondazione Italiana Linfomi - ETS | Lymphoma, Follicular | 01/23 | 08/27 | | |
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) |
|
|
| Active, not recruiting | 3 | 250 | Europe, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 04/25 | 08/26 | | |
| Active, not recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa | Loxo Oncology, Inc., Eli Lilly and Company | Lymphoma, Mantle-Cell | 12/25 | 07/26 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
| Recruiting | 3 | 430 | Europe | Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses | Fondazione Italiana Linfomi ONLUS, GRADE Onlus | Diffuse Large B-Cell Lymphoma, Elderly Patients | 09/25 | 09/30 | | |
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma |
|
|
| Recruiting | 3 | 602 | Europe | Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B) | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 07/28 | 07/30 | | |
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients |
|
|
| Recruiting | 3 | 120 | Europe | Rituximab, Truxima, Zanubrutinib, Brukinsa | International Extranodal Lymphoma Study Group (IELSG) | Splenic Marginal Zone Lymphoma | 05/29 | 05/29 | | |
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi |
|
|
| Recruiting | 3 | 190 | Europe | Radiotherapy, Radiotherapy plus Obinutuzumab | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Follicular Lymphoma | 04/31 | 04/31 | | |
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
| Recruiting | 2 | 160 | Europe | Nivolumab 10 MG/ML | Medical University of Gdansk, Medical Research Agency | Hodgkin Lymphoma | 09/22 | 07/26 | | |
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide |
|
|
| Terminated | 2 | 5 | Europe | Rituximab, Chemotherapy, Tenofovir alafenamide | Gruppo Italiano Malattie EMatologiche dell'Adulto | Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | 05/24 | 05/24 | | |
| Not yet recruiting | 2 | 56 | Europe | Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 09/28 | 09/33 | | |
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
|
|
| Recruiting | 2 | 249 | Europe, Canada, US, RoW | Pirtobrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | 06/28 | 12/28 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy |
|
|
| Recruiting | 2 | 28 | Europe | Tislelizumab | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/27 | 11/29 | | |
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma |
|
|
| Withdrawn | 2 | 150 | Europe | R-DHAP, Pola-R-DHAP | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent | 01/29 | 01/29 | | |
| Recruiting | 1/2 | 122 | Europe | Atezolizumab, BEGEV, Bendamustine, Gemcitabine, Vinorelbine | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Relapsed or Refractory Hodgkin's Lymphoma | 04/27 | 04/30 | | |
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy |
|
|
| Recruiting | N/A | 321 | Europe | Venetoclax | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia | 01/23 | 10/25 | | |
CLL2423, NCT05803395: Incidence of Severe COVID-19 Infection in Patients With CLL or B-NHL Who Received Pre-exposure Prophylaxis With Tixagevimab and Cilgavimab in Italy. |
|
|
| Recruiting | N/A | 954 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto, Fondazione Italiana Linfomi | Chronic Lymphocytic Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, COVID-19 | 09/24 | 09/24 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
FIL_FOLL-BIO, NCT05816850: Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial |
|
|
| Recruiting | N/A | 654 | Europe | EZH2 mutations/CNAs by droplet digital PCR (ddPCR), EZH2-derived gene expression signature by RNA-Seq | Fondazione Italiana Linfomi - ETS | Follicular Lymphoma | 06/25 | 06/26 | | |
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval. |
|
|
| Not yet recruiting | N/A | 125 | Europe | Zanubrutinib | Fondazione Italiana Linfomi - ETS | Waldenström's Macroglobulinemia (WM) | 07/26 | 07/26 | | |
NCT06774677: Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management |
|
|
| Recruiting | N/A | 50 | Europe | | IRCCS Azienda Ospedaliero-Universitaria di Bologna | Hairy Cell Leukemia (HCL) | 08/26 | 08/26 | | |
NCT05524298: Quality of Life on Elderly Patients with Low Grade Non-Hodgkin Lymphoma |
|
|
| Recruiting | N/A | 150 | Europe | | Fondazione Italiana Linfomi - ETS | Low Grade Non-Hodgkin's Lymphoma, Adult | 02/25 | 02/25 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
| Pinto, Antonio |
| Completed | 3 | 500 | Europe | Doxorubicin, Bleomycin, Vinblastine, Dacarbazine | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/21 | 11/24 | | |
FIL-RougeBIO, NCT05066555: Circulating Tumor DNA Genotyping for Biological Monitoring of Patients Treated in the FIL-Rouge Clinical Trial |
|
|
| Completed | 3 | 100 | Europe | | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/21 | 11/24 | | |
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
| Terminated | 2 | 22 | Europe | ERDAFITINIB, JNJ -42756493, WHO NUMBER 10147 | Lung Cancer Group Cologne | Lung Cancer, NSCLC, Pulmonary Neoplasm, Squamous Cell Lung Cancer, NSCLC Stage IV | 09/22 | 10/22 | | |
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance |
|
|
| Active, not recruiting | 2 | 75 | Europe | Ibrutinib, IMBRUVICA (commercial name) | Fondazione Italiana Linfomi - ETS, Janssen-Cilag S.p.A. | DLBCL | 07/24 | 07/27 | | |
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients. |
|
|
| Recruiting | 2 | 49 | Europe | Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at standard dose (R-BAC, Rituximab - Bendamustine, Ara-C)), Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy at reduced dose (R-BAC, Rituximab - Bendamustine, Ara-C) | Fondazione Italiana Linfomi - ETS | Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 04/26 | 04/29 | | |
| Recruiting | 2 | 244 | Europe, Canada, US, RoW | Selinexor, KPT-330 | Karyopharm Therapeutics Inc | Diffuse Large B-cell Lymphoma | 04/27 | 11/27 | | |
|
|
|
|
|
|
|
|
|
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy |
|
|
| Recruiting | 2 | 28 | Europe | Tislelizumab | Fondazione Italiana Linfomi - ETS | Hodgkin Lymphoma | 11/27 | 11/29 | | |
| Recruiting | 1/2 | 60 | Europe, US | EO2463, lenalidomide, Revlimid, rituximab, MabThera | Enterome | Follicular Lymphoma, Marginal Zone Lymphoma | 05/26 | 05/32 | | |
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
|
|
| Completed | 1 | 106 | Europe, US | Tinostamustine, EDO-S101 | Mundipharma Research Limited | Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma | 05/23 | 11/23 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
NCT06600568: Novel Therapeutic Approach for Human T-cell Malignancies |
|
|
| Recruiting | N/A | 120 | Europe | Translation analysis | Istituto Oncologico Veneto IRCCS, Istituto Nazionale Tumori IRCSS-Fondazione G.Pascale | T-Cell Leukemia/Lymphoma, Adult | 07/26 | 07/26 | | |
| Frigeri, Ferdinando |
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) |
|
|
| Recruiting | N/A | 200 | Europe | | Incyte Biosciences Italy S.r.l, Advice Pharma Group srl | DLBCL - Diffuse Large B Cell Lymphoma | 06/25 | 06/27 | | |
| Peng, Liu |
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 2/3 | 501 | Europe, US, RoW | Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy) | Karyopharm Therapeutics Inc | Relapsed/refractory Diffuse Large B-cell Lymphoma | 12/24 | 12/25 | | |
